Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

11289	Companies
250837	Keywords
179636	Articles
136674	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 09/15/2025 at 07:00, 1 year 1 month ago

Biophytis Secures public funding in Brazil for Obesity Phase 2 Trial and Signs Agreements with Leading local Clinical Partners
Biophytis secures public funding in Brazil for Obesity Phase 2 trial and signs agreements with leading local clinical partners, strengthening its OBA Phase 2 program and obtaining non-dilutive funding support through EMBRAPII

Biophytis Public Funding EMBRAPII Obesity Phase 2 Trial Clinical Partners
BRIEF

published on 09/11/2025 at 07:05, 1 year 1 month ago

Biophytis Announces Phase 3 Sarcopenia Trial for BIO101 in Europe and Asia

Age-related Diseases BIO101 Sarcopenia Clinical Trial Biophytis Strategy Asia And Europe
REGULATED PRESS RELEASE

published on 09/11/2025 at 07:00, 1 year 1 month ago

Biophytis unveils Phase 3 Sarcopenia Trial Strategy with BIO101 in Europe and Asia
Biophytis announces Phase 3 Sarcopenia Trial Strategy with BIO101 targeting age-related sarcopenia in Europe and Asia, aiming to address a significant unmet medical need and commercial market

Biophytis Clinical Trial Sarcopenia Phase 3 BIO101
BRIEF

published on 09/03/2025 at 07:05, 1 year 2 months ago

Biophytis Advances Obesity Treatment with EMA Approval

Biophytis Obesity Treatment Clinical Trial BIO101 EMA Authorization
REGULATED PRESS RELEASE

published on 09/03/2025 at 07:00, 1 year 2 months ago

Biophytis obtains EMA authorization to launch its Phase 2 clinical trial in obesity
Biophytis obtains EMA authorization to launch Phase 2 clinical trial of BIO101 in obesity, marking a significant regulatory milestone in Europe

Biophytis Phase 2 Clinical Trial Obesity EMA Authorization Regulatory Milestone
BRIEF

published on 09/01/2025 at 07:05, 1 year 2 months ago

Biophytis Announces Phase 2 Obesity Trial with BIO101

Biophytis Phase 2 Trial BIO101 Obesity Muscle Wasting
REGULATED PRESS RELEASE

published on 09/01/2025 at 07:00, 1 year 2 months ago

Biophytis unveils Phase 2 Obesity Trial Strategy with BIO101 in Europe and Brazil
Biophytis reveals Phase 2 Obesity Trial Strategy for BIO101 in Europe and Brazil, targeting muscle wasting in obese patients. Expanding therapeutic horizons and commercial prospects

Biophytis Phase 2 BIO101 Muscle Wasting Obesity Trial
PRESS RELEASE

published on 09/01/2025 at 06:59, 1 year 2 months ago

Biophytis unveils Phase 2 Obesity Trial Strategy with BIO101 in Europe and Brazil
Biophytis unveils Phase 2 Obesity Trial Strategy for BIO101 in Europe and Brazil, targeting muscle wasting associated with obesity. The new program broadens potential and value-creation opportunities globally

Biophytis Phase 2 BIO101 Muscle Wasting Obesity Trial
BRIEF

published on 08/28/2025 at 07:05, 1 year 2 months ago

Biophytis Gains Regulatory Approval for Phase 3 Sarcopenia Trial

Biophytis Regulatory Approval Clinical Trial Sarcopenia Phase 3
REGULATED PRESS RELEASE

published on 08/28/2025 at 07:00, 1 year 2 months ago

Biophytis Receives EMA and Belgian Regulatory Approval to Initiate Phase 3 Sarcopenia Clinical Trial
Biophytis receives EMA and Belgian regulatory approval for Phase 3 sarcopenia clinical trial, marking a significant milestone in developing therapies for muscle loss in aging individuals

Biophytis Sarcopenia Phase 3 EMA Belgian Regulatory Approval

Accesswire

Published on 11/05/2026 at 22:05, 12 minutes ago

Innodata Reports Record Third Quarter 2026 Results
Published on 11/05/2026 at 22:01, 16 minutes ago

Unusual Machines Third Quarter 2026 Shareholder Letter
Published on 11/05/2026 at 15:20, 6 hours 57 minutes ago

MicroVision and LAKE FUSION Technologies Sign Multi-Year Strategic Partnership Agreement for IRIS(TM) Lidar Sensors
Published on 11/05/2026 at 14:31, 7 hours 46 minutes ago

First Breach Close-Quarters Strike (CQS) Drone Successfully Completes Full Mission Profile
Published on 11/05/2026 at 14:25, 7 hours 52 minutes ago

Polaris Renewable Energy Announces Q3 2026 Results

View all ACCESSWIRE

EQS Group

Published on 11/05/2026 at 22:05, 11 minutes ago

Quantinuum Reports Third Quarter 2026 Results and Raises Full-Year Revenue Outlook
Published on 11/05/2026 at 20:38, 1 hour 38 minutes ago

freenet uses funds from Ceconomy sale for waipu.tv acquisition and share buyback
Published on 11/05/2026 at 20:37, 1 hour 39 minutes ago

EQS-Adhoc: freenet AG decides on share buyback programme for up to EUR 75 million
Published on 11/05/2026 at 19:45, 2 hours 31 minutes ago

Stabilus SE fulfills forecast for fiscal 2026 and adjusts 2030 medium-term targets
Published on 11/05/2026 at 19:41, 2 hours 35 minutes ago

EQS-Adhoc: Stabilus SE – Around €67 million in non-cash impairments reduce EBIT for FY2026; Preliminary Q4 FY2026 figures: Revenue and adjusted EBIT exceed market expectations, while adjusted free cash flow fall

Les Echos

Published on 11/05/2026 at 18:21, 3 hours 55 minutes ago

Total number of voting rights and shares making up the share capital at October 31, 2026
Published on 11/05/2026 at 17:50, 4 hours 26 minutes ago

NRJ GROUP - Financial information Q3 2026
Published on 11/05/2026 at 17:45, 4 hours 32 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 11/05/2026 at 17:29, 4 hours 47 minutes ago

Notice of exercise of early redemption option of the subordinated note ISIN FR0010406082
Published on 11/05/2026 at 10:16, 12 hours ago

Growth acceleration confirmed in the third quarter of 2026 All businesses growing, revenue up +6,5%

View all LES ECHOS COMFI WIRE